Combinations of cannabinoids and n-acylethanolamines

Abstract

The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

1 - 48 . (canceled) 
     
     
         49 . A method for preventing or treating pain in a human subject in need thereof, comprising
 administering to the subject a pharmaceutical composition in a therapeutically-effective amount to prevent or treat the pain,   wherein the composition comprises at least one phyto-cannabinoid or a salt thereof, and at least one N-acylethanolamine or a salt thereof,   wherein the at least one phyto-cannabinoid or salt thereof and the at least one N-acylethanolamine or salt thereof are present in the composition in a molar ratio of about 1:0.2 to about 1:2000, and   wherein the at least one phyto-cannabinoid is tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), a salt thereof, or any combination thereof.   
     
     
         50 . The method of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:0.2 to about 1:5. 
     
     
         51 . The method of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:0.5 to about 1:2. 
     
     
         52 . The method of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:15 to about 1:1800. 
     
     
         53 . The method of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:25 to about 1:450. 
     
     
         54 . The method of  claim 49 , wherein the molar ratio between the at least one phyto-cannabinoid or salt thereof, and the at least one N-acylethanolamine or salt thereof is between about 1:50 to about 1:100. 
     
     
         55 . The method of  claim 49 , wherein the at least one phyto-cannabinoid is CBD or a salt thereof. 
     
     
         56 . The method of  claim 49 , wherein the pharmaceutical composition comprises about 200-1800 mg of N-acylethanolamine or salt thereof. 
     
     
         57 . The method of  claim 56 , wherein the pharmaceutical composition comprises about 250 mg, about 500 mg, about 750 mg, about 1000 mg or about 1500 mg of N-acylethanolamine or salt thereof. 
     
     
         58 . The method of  claim 49 , wherein the at least one N-acylethanolamine is N-palmitoylethanolamine (PEA), Me-palmitoylethanolamide (Me-PEA), palmitoylcyclohexamide, palmitoylbutylamide, palmitoylisopropylamide, oleoylethanolamine (OEA), palmitoylisopropylamide (PIA), a salt thereof, or any combination thereof. 
     
     
         59 . The method of  claim 58 , wherein the at least one N-acylethanolamine is PEA or a salt thereof. 
     
     
         60 . The method of  claim 49 , wherein the pharmaceutical composition comprises CBD or a salt thereof, and PEA or a salt thereof. 
     
     
         61 . The method of  claim 49 , wherein the pharmaceutical composition comprises about 0.5-10 mg of the phyto-cannabinoid or salt thereof, and about 200-1800 mg of PEA or a salt thereof. 
     
     
         62 . The method of  claim 49 , wherein the pharmaceutical composition comprises about 2.5-10 mg of the phyto-cannabinoid or salt thereof and about 250-1000 mg of PEA or a salt thereof. 
     
     
         63 . The method of  claim 49 , wherein the pharmaceutical composition comprises about 2.5 mg, about 5 mg, about 7.5 mg or about 10 mg of the phyto-cannabinoid or salt thereof, and about 250 mg, about 500 mg, about 750 mg or about 1000 mg of PEA or a salt thereof. 
     
     
         64 . The method of  claim 49 , wherein the pharmaceutical composition is formulated for oral, oral mucosal, nasal, sublingual, inhalational, topical, rectal, vaginal, parenteral, intravenous, intramuscular, or subcutaneous administration. 
     
     
         65 . The method of  claim 49 , wherein the administration of the at least one phyto-cannabinoid and the N-acylethanolamine is repeated. 
     
     
         66 . The method of  claim 49 , wherein the pain is an acute pain, chronic pain, or neuropathic pain.